ClinicalTrials.gg
CompletedNCT03104413Updated Jun 14, 2022Results posted

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

A Phase 3 interventional study of placebo for risankizumab IV and risankizumab SC in Crohn's Disease, sponsored by AbbVie. Completed at 403 sites in 43 countries. Open to participants aged 16 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-06-14.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
618
Allocation
Randomized
Ages
16 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing risankizumab in Crohn Disease — 7 open to participants now, 10 under way, 6 of them phase 3. risankizumab · Crohn Disease.

Enrollment
4th of 16
618 · median 275
Started
2017
with 1 other
Phase 3
8 of 16
3 open now
Registered
3rd of 16
by date
Lead sponsor
12 of 16
AbbVie

Among the 16 studies testing risankizumab in Crohn Disease, this one is the 4th largest by enrollment, is one of 2 that started in 2017, is one of 8 in phase 3, and was the 3rd registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

7 of the 16 studies testing risankizumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About risankizumab

risankizumab: first FDA approval 2019 (SKYRIZI), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 16 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing risankizumab in Crohn Disease, or all of them as a file.
02

Study summary

The objective of Study M15-991 is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in participants with moderately to severely active CD.

03

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • ABBV-066
  • BI 655066
04

Who can participate

Ages eligible
16 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged >=18 to \<= 80 years, or minimum age of adult consent according to local regulations, at the Baseline Visit. Where locally permissible, participants 16 to \< 18 years of age who meet the definition of Tanner stage 5 for development at the Baseline Visit.
  • Confirmed diagnosis of CD for at least 3 months prior to Baseline.
  • Crohn's disease activity index (CDAI) score 220 - 450 at Baseline.
  • Confirmed diagnosis of moderate to severe CD as assessed by stool frequency (SF), abdominal pain (AP) score, and Simple Endoscopic Score for Crohn's Disease (SES-CD).
  • Demonstrated intolerance or inadequate response to biologic therapy for CD.
  • If female, participant must meet the recommendations.

Exclusion criteria

Exclusion Criteria:

  • Participant with a current diagnosis of ulcerative colitis or indeterminate colitis.
  • Participants with unstable doses of concomitant Crohn's disease therapy.
  • Receipt of Crohn's disease approved biologic agents (infliximab, adalimumab, certolizumab, vedolizumab, natalizumab within 8 weeks prior to Baseline or ustekinumab within 12 weeks prior to Baseline), or any biologic or other agent or procedure within minimally 35 days or 5 half-lives prior to Baseline, whichever is longer.
  • Prior exposure to p19 inhibitors (e.g., risankizumab).
  • Complications of Crohn's disease.
  • Having an ostomy or ileoanal pouch.
  • Known active Coronavirus Disease 2019 (COVID-19) infection.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
618 participants (actual)

Study arms

  • Experimental
    Risankizumab Dose 1 (Induction Period 1)

    Participants randomized to receive risankizumab dose 1 in Induction Period 1.

    Drug: risankizumab IV

  • Experimental
    Risankizumab Dose 2 (Induction Period 1)

    Participants randomized to receive risankizumab dose 2 in Induction Period 1.

    Drug: risankizumab IV

  • Placebo comparator
    Placebo (Induction Period 1)

    Participants randomized to receive placebo for risankizumab in Induction Period 1.

    Drug: placebo for risankizumab IV

  • Experimental
    Risankizumab Dose 1 (Induction Period 2)

    Participants who received placebo in Period 1 and participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Period 2.

    Drug: risankizumab IV

  • Experimental
    Risankizumab Dose 2 (Induction Period 2)

    Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection in Period 2.

    Drug: risankizumab SC

  • Experimental
    Risankizumab Dose 3 (Induction period 2)

    Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 3 administered by subcutaneous (SC) injection in Period 2.

    Drug: risankizumab SC

Interventions

  • Drugplacebo for risankizumab IV

    placebo for risankizumab administered as intravenous (IV) infusion.

  • risankizumab administered by subcutaneous (SC) injection

    Also known as: ABBV-066 BI 655066, SKYRIZI

  • risankizumab administered as intravenous (IV) infusion.

    Also known as: ABBV-066 BI 655066, SKYRIZI

06

What researchers measure

Primary outcomes

  1. US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission

    The CDAI consists of 8 components; 7 are based on participant diary entries, participant interviews, physical examinations, measurement of body weight and height and 1 is based on laboratory analysis. CDAI clinical remission of Crohn's disease is defined as CDAI \< 150.

    Time frame: Week 12

  2. US Specific: Percentage of Participants With Endoscopic Response

    The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD \> 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).

    Time frame: Week 12

  3. Global Outside of US: Percentage of Participants With Clinical Remission

    Clinical remission is defined as using the average daily Stool Frequency (SF) ≤ 2.8 and not worse than Baseline AND average daily Abdominal Pain (AP) score ≤ 1 and not worse than Baseline.

    Time frame: Week 12

  4. Global Outside of US: Percentage of Participants With Endoscopic Response

    The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD \> 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).

    Time frame: Week 12

Secondary outcomes

  1. US Specific: Percentage of Participants With Clinical Remission

    Clinical remission is defined as using the average daily Stool Frequency (SF) ≤ 2.8 and not worse than Baseline AND average daily Abdominal Pain (AP) score ≤ 1 and not worse than Baseline.

    Time frame: Week 12

  2. US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response

    Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline.

    Time frame: Week 4

  3. US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response

    Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline.

    Time frame: Week 12

  4. US Specific: Change From Baseline of Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue

    The FACIT-Fatigue scale is a 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four point Likert scale. The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from baseline indicates improvement.

    Time frame: Week 12

  5. US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission

    Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical remission of Crohn's disease is defined as CDAI \< 150.

    Time frame: Week 4

  6. US Specific: Percentage of Participants With CDAI Clinical Response and Endoscopic Response

    Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline. Endoscopic response was a decrease in Simplified Endoscopic Score for Crohn's Disease (SES-CD) \> 50% from Baseline (or for subjects with isolated ileal disease and a Baseline SES-CD of 4, at least a 2 point reduction from Baseline).

    Time frame: Week 12

  7. US Specific: Percentage of Participants With Stool Frequency (SF) Remission

    Stool Frequency (SF) remission is defined as an average daily SF \<= 2.8 and not worse than baseline.

    Time frame: Week 12

  8. US Specific: Percentage of Participants With Abdominal Pain (AP) Remission

    The Abdominal Pain rating is an assessment that is graded from 0 to 3: 0= None, 1= Mild, 2= Moderate and 3= Severe. AP remission is defined as average daily AP score \<= 1 and not worse than baseline.

    Time frame: Week 12

  9. US Specific: Percentage of Participants With Endoscopic Remission

    Endoscopic remission: SES-CD ≤ 4 and at least a 2 point reduction versus baseline and no subscore greater than 1 in any individual variable

    Time frame: Week 12

  10. US Specific: Percentage of Participants With Enhanced Clinical Response

    Enhanced clinical response: ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in average daily AP score and both not worse than Baseline, and/or clinical remission

    Time frame: Week 4

  11. US Specific: Percentage of Participants With Ulcer-Free Endoscopy

    Ulcer-free endoscopy: SES-CD ulcerated surface subscore of 0 in subjects with SES-CD ulcerated surface subscore ≥ 1 at Baseline

    Time frame: Week 12

  12. US Specific: Percentage of Participants With Enhanced Clinical Response

    Enhanced clinical response: ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in average daily AP score and both not worse than Baseline, and/or clinical remission

    Time frame: Week 12

  13. US Specific: Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs), in Participants With EIMs at Baseline Baseline

    Manifestations of Crohn's disease in areas of the body other than the digestive tract, including eyes, skin, joints, mouth, and liver.

    Time frame: Week 12

  14. US Specific: Percentage of Participants With CD-Related Hospitalization

    Participants with at least one admission to the hospital due to Crohn's Disease.

    Time frame: Up to Week 12

  15. US Specific: Percentage of Participants Without Draining Fistulas in Participants With Draining Fistulas at Baseline

    Participants without draining fistulas at Week 12 in participants who had draining fistulas at baseline.

    Time frame: Week 12

  16. Global Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission

    The CDAI consists of 8 components; 6 are based on participant diary entries, participant interviews, and physical examinations, and 2 are based on laboratory analysis, and measurement of body weight and height. CDAI clinical remission of Crohn's disease is defined as CDAI \< 150.

    Time frame: Week 12

  17. Global Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response

    Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline.

    Time frame: Week 4

  18. Global Outside of US: Percentage of Participants With Clinical Remission

    Clinical remission is defined as using the average daily Stool Frequency (SF) ≤ 2.8 and not worse than Baseline AND average daily Abdominal Pain (AP) score ≤ 1 and not worse than Baseline.

    Time frame: Week 4

  19. Global Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response

    Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline.

    Time frame: Week 12

  20. Global Outside of US: Change From Baseline of Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue

    The FACIT-Fatigue scale is a 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four point Likert scale. The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from baseline indicates improvement.

    Time frame: Week 12

  21. Global Outside of US: Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score

    The IBDQ is a 32-item (ranges 1 - 7) self-report questionnaire for patients with IBD to evaluate the patient reported outcomes across 4 dimensions: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). The IBDQ total Score ranges from 32 to 224 with a higher score indicating better outcome.

    Time frame: Week 12

  22. Global Outside of US: Percentage of Participants With Enhanced Clinical Response and Endoscopic Response

    Enhanced clinical response was defined as ≥ 60% decrease in average daily Stool Frequency and/or ≥ 35% decrease in average daily Abdominal Pain score and both not worse than baseline, and/or clinical remission. Endoscopic Response was defined as a decrease in Simplified Endoscopic Score for Crohn's Disease (SES-CD) \> 50% from Baseline (or for subjects with isolated ileal disease and a Baseline SES-CD of 4, at least a 2 point reduction from Baseline).

    Time frame: Week 12

  23. Global Outside of US:: Percentage of Participants With Endoscopic Remission

    Endoscopic remission: SES-CD ≤ 4 and at least a 2 point reduction versus baseline and no subscore greater than 1 in any individual variable

    Time frame: Week 12

  24. Global Outside of US: Percentage of Participants With Enhanced Clinical Response

    Enhanced clinical response: ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in average daily AP score and both not worse than Baseline, and/or clinical remission

    Time frame: Week 4

  25. Global Outside of US: Percentage of Participants With Ulcer-Free Endoscopy

    Ulcer-free endoscopy: SES-CD ulcerated surface subscore of 0 in subjects with SES-CD ulcerated surface subscore ≥ 1 at Baseline

    Time frame: Week 12

  26. Global Outside of US: Percentage of Participants With Enhanced Clinical Response

    Enhanced clinical response: ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in average daily AP score and both not worse than Baseline, and/or clinical remission

    Time frame: Week 12

  27. Global Outside of US: Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs), in Participants With EIMs at Baseline Baseline

    Manifestations of Crohn's disease in areas of the body other than the digestive tract, including eyes, skin, joints, mouth, and liver.

    Time frame: Week 12

  28. Global Outside of US: Percentage of Participants With CD-Related Hospitalization

    Participants with at least one admission to the hospital due to Crohn's Disease.

    Time frame: Week 12

  29. Global Outside of US: Percentage of Participants Without Draining Fistulas in Participants With Draining Fistulas at Baseline

    Participants without draining fistulas at Week 12 in participants who had draining fistulas at baseline.

    Time frame: Week 12

  30. Global Outside of US: Change From Baseline in Work Productivity and Impairment Questionnaire - Crohn's Disease (WPAI-CD) Overall Work Impairment

    WPAI: CD is a questionnaire used to evaluate lost productivity due to CD ; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. Total work productivity impairment takes into account both hours missed due to CD symptoms and the patient's assessment of the degree to which CD affected their productivity while working (overall work impairment \[OWI\]). WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.

    Time frame: Week 12

  31. Global Outside of US: Change From Baseline in Short Form-36 (SF-36) Physical Component Summary (PCS) Score

    The Short Form-36 Health Survey determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement.

    Time frame: Week 12

07

Results

Posted Jun 14, 2022

Participant flow

Subjects were randomized to receive 600mg risankizumab, 1200mg risankizumab or placebo during the double-blind, placebo-controlled Period 1. At Week 12, subjects who do not achieve clinical response were randomized into Period 2 to receive 180mg risankizumab, 360mg risankizumab or 1200mg risankizumab. Subjects who received placebo received 1200mg.

Induction Period 1
Participant flow — Induction Period 1
MilestonePlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)Risankizumab Dose 180mg (Induction Period 2)Risankizumab 360mg (Induction Period 2)Risankizumab 1200mg (Induction Period 2)Placebo/Risankizumab 1200mg (Induction Period 2)
Started2072062050000
Completed1862021990000
Not completed21460000
Induction Period 2
Participant flow — Induction Period 2
MilestonePlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)Risankizumab Dose 180mg (Induction Period 2)Risankizumab 360mg (Induction Period 2)Risankizumab 1200mg (Induction Period 2)Placebo/Risankizumab 1200mg (Induction Period 2)
Started00041424286
Completed00039393876
Not completed00023410

Outcome measures

PrimaryUS Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission

The CDAI consists of 8 components; 7 are based on participant diary entries, participant interviews, physical examinations, measurement of body weight and height and 1 is based on laboratory analysis. CDAI clinical remission of Crohn's disease is defined as CDAI \< 150.

Time frame:
Week 12
Reported as:
Number · percentage of participants
US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission
percentage of participantsPlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)
US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission19.8 (14.1 to 25.5)42.0 (34.9 to 49.0)40.3 (33.4 to 47.3)
Statistical analysis
  • Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 22.1 · 95% CI 13.1 to 31.0
  • Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = < 0.001 · Adjusted risk difference: 20.5 · 95% CI 11.6 to 29.5
PrimaryUS Specific: Percentage of Participants With Endoscopic Response

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD \> 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).

Time frame:
Week 12
Reported as:
Number · percentage of participants
US Specific: Percentage of Participants With Endoscopic Response
percentage of participantsPlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)
US Specific: Percentage of Participants With Endoscopic Response11.2 (6.7 to 15.8)28.8 (22.4 to 35.3)34.2 (27.4 to 40.9)
Statistical analysis
  • Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = < 0.001 · Adjusted risk difference: 17.6 · 95% CI 9.9 to 25.4
  • Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 23.1 · 95% CI 15.1 to 31.1
PrimaryGlobal Outside of US: Percentage of Participants With Clinical Remission

Clinical remission is defined as using the average daily Stool Frequency (SF) ≤ 2.8 and not worse than Baseline AND average daily Abdominal Pain (AP) score ≤ 1 and not worse than Baseline.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Global Outside of US: Percentage of Participants With Clinical Remission
percentage of participantsPlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)
Global Outside of US: Percentage of Participants With Clinical Remission11.2 (6.7 to 15.8)28.8 (22.4 to 35.3)34.2 (27.4 to 40.9)
Statistical analysis
  • Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 17.6 · 95% CI 9.9 to 25.4
  • Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 23.1 · 95% CI 15.1 to 31.1
SecondaryUS Specific: Percentage of Participants With Clinical Remission

Clinical remission is defined as using the average daily Stool Frequency (SF) ≤ 2.8 and not worse than Baseline AND average daily Abdominal Pain (AP) score ≤ 1 and not worse than Baseline.

Time frame:
Week 12
Reported as:
Number · percentage of participants
US Specific: Percentage of Participants With Clinical Remission
percentage of participantsPlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)
US Specific: Percentage of Participants With Clinical Remission19.3 (13.6 to 24.9)34.6 (27.8 to 41.3)39.8 (32.8 to 46.7)
Statistical analysis
  • Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = 0.001 · Adjusted risk difference: 15.2 · 95% CI 6.4 to 24.0
  • Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 20.4 · 95% CI 11.5 to 29.3
SecondaryUS Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response

Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline.

Time frame:
Week 4
Reported as:
Number · percentage of participants
US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response
percentage of participantsPlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)
US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response20.9 (15.0 to 26.7)36.6 (29.8 to 43.5)32.5 (25.8 to 39.1)
Statistical analysis
  • Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = 0.001 · Adjusted risk difference: 15.7 · 95% CI 6.8 to 24.6
  • Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = 0.008 · Adjusted risk difference: 11.8 · 95% CI 3.0 to 20.5
SecondaryUS Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response

Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline.

Time frame:
Week 12
Reported as:
Number · percentage of participants
US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response
percentage of participantsPlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)
US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response30.0 (23.4 to 36.6)59.5 (52.5 to 66.5)60.7 (53.8 to 67.7)
Statistical analysis
  • Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = < 0.001 · Adjusted risk difference: 29.4 · 95% CI 19.9 to 39.0
  • Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 30.6 · 95% CI 21.1 to 40.1
SecondaryUS Specific: Change From Baseline of Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue

The FACIT-Fatigue scale is a 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four point Likert scale. The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from baseline indicates improvement.

Time frame:
Week 12
Reported as:
Least squares mean · units on a scale
US Specific: Change From Baseline of Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue
units on a scalePlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)
US Specific: Change From Baseline of Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue7.7 ± 0.8710.5 ± 0.8110.8 ± 0.81
Statistical analysis
  • Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1) · Mixed-Effect Model Repeat Measurement · p = 0.020 · Ls mean difference: 2.8 · 95% CI 0.4 to 5.1
  • Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1) · Mixed-Effect Model Repeat Measurement · p = 0.010 · Ls mean difference: 3.0 · 95% CI 0.7 to 5.3
SecondaryUS Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission

Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical remission of Crohn's disease is defined as CDAI \< 150.

Time frame:
Week 4
Reported as:
Number · percentage of participants
US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission
percentage of participantsPlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)
US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission11.2 (6.7 to 15.8)20.9 (15.2 to 26.7)19.4 (13.8 to 25.0)
Statistical analysis
  • Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = 0.010 · Adjusted risk difference: 9.6 · 95% CI 2.3 to 16.9
  • Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = 0.023 · Adjusted risk difference: 8.2 · 95% CI 1.1 to 15.3
SecondaryUS Specific: Percentage of Participants With CDAI Clinical Response and Endoscopic Response

Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline. Endoscopic response was a decrease in Simplified Endoscopic Score for Crohn's Disease (SES-CD) \> 50% from Baseline (or for subjects with isolated ileal disease and a Baseline SES-CD of 4, at least a 2 point reduction from Baseline).

Time frame:
Week 12
Reported as:
Number · percentage of participants
US Specific: Percentage of Participants With CDAI Clinical Response and Endoscopic Response
percentage of participantsPlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)
US Specific: Percentage of Participants With CDAI Clinical Response and Endoscopic Response5.3 (2.1 to 8.6)20.5 (14.7 to 26.2)23.0 (17.1 to 29.0)
Statistical analysis
  • Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 15.0 · 95% CI 8.5 to 21.5
  • Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 17.8 · 95% CI 11.1 to 24.5
SecondaryUS Specific: Percentage of Participants With Stool Frequency (SF) Remission

Stool Frequency (SF) remission is defined as an average daily SF \<= 2.8 and not worse than baseline.

Time frame:
Week 12
Reported as:
Number · percentage of participants
US Specific: Percentage of Participants With Stool Frequency (SF) Remission
percentage of participantsPlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)
US Specific: Percentage of Participants With Stool Frequency (SF) Remission28.3 (21.9 to 34.8)46.1 (39.9 to 53.1)48.7 (41.6 to 55.8)
Statistical analysis
  • Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 17.5 · 95% CI 8.0 to 26.9
  • Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 20.3 · 95% CI 10.8 to 29.8
SecondaryUS Specific: Percentage of Participants With Abdominal Pain (AP) Remission

The Abdominal Pain rating is an assessment that is graded from 0 to 3: 0= None, 1= Mild, 2= Moderate and 3= Severe. AP remission is defined as average daily AP score \<= 1 and not worse than baseline.

Time frame:
Week 12
Reported as:
Number · percentage of participants
US Specific: Percentage of Participants With Abdominal Pain (AP) Remission
percentage of participantsPlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)
US Specific: Percentage of Participants With Abdominal Pain (AP) Remission36.4 (29.5 to 43.3)58.1 (51.1 to 65.1)59.2 (52.2 to 66.1)
Statistical analysis
  • Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 21.8 · 95% CI 12.1 to 31.6
  • Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 22.7 · 95% CI 13.0 to 32.5
SecondaryUS Specific: Percentage of Participants With Endoscopic Remission

Endoscopic remission: SES-CD ≤ 4 and at least a 2 point reduction versus baseline and no subscore greater than 1 in any individual variable

Time frame:
Week 12
Reported as:
Number · percentage of participants
US Specific: Percentage of Participants With Endoscopic Remission
percentage of participantsPlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)
US Specific: Percentage of Participants With Endoscopic Remission4.3 (1.4 to 7.2)19.4 (13.8 to 25.1)20.4 (14.7 to 26.1)
Statistical analysis
  • Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 15.0 · 95% CI 8.9 to 21.2
  • Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 16.2 · 95% CI 9.9 to 22.4
SecondaryUS Specific: Percentage of Participants With Enhanced Clinical Response

Enhanced clinical response: ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in average daily AP score and both not worse than Baseline, and/or clinical remission

Time frame:
Week 4
Reported as:
Number · percentage of participants
US Specific: Percentage of Participants With Enhanced Clinical Response
percentage of participantsPlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)
US Specific: Percentage of Participants With Enhanced Clinical Response31.6 (24.9 to 38.2)45.0 (38.0 to 52.1)38.7 (31.8 to 45.7)
Statistical analysis
  • Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = 0.006 · Adjusted risk difference: 13.6 · 95% CI 4.0 to 23.3
  • Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = 0.142 · Adjusted risk difference: 7.1 · 95% CI -2.4 to 16.6
SecondaryUS Specific: Percentage of Participants With Ulcer-Free Endoscopy

Ulcer-free endoscopy: SES-CD ulcerated surface subscore of 0 in subjects with SES-CD ulcerated surface subscore ≥ 1 at Baseline

Time frame:
Week 12
Reported as:
Number · percentage of participants
US Specific: Percentage of Participants With Ulcer-Free Endoscopy
percentage of participantsPlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)
US Specific: Percentage of Participants With Ulcer-Free Endoscopy4.3 (1.4 to 7.2)13.8 (8.9 to 18.7)15.4 (10.2 to 20.5)
Statistical analysis
  • Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = 0.001 · Adjusted risk difference: 9.4 · 95% CI 3.8 to 15.1
  • Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 11.2 · 95% CI 5.3 to 17.0
SecondaryUS Specific: Percentage of Participants With Enhanced Clinical Response

Enhanced clinical response: ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in average daily AP score and both not worse than Baseline, and/or clinical remission

Time frame:
Week 12
Reported as:
Number · percentage of participants
US Specific: Percentage of Participants With Enhanced Clinical Response
percentage of participantsPlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)
US Specific: Percentage of Participants With Enhanced Clinical Response39.1 (32.1 to 46.1)61.8 (54.9 to 68.7)59.2 (52.2 to 66.1)
Statistical analysis
  • Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 22.8 · 95% CI 13.0 to 32.5
  • Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 20.0 · 95% CI 10.2 to 29.9
SecondaryUS Specific: Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs), in Participants With EIMs at Baseline Baseline

Manifestations of Crohn's disease in areas of the body other than the digestive tract, including eyes, skin, joints, mouth, and liver.

Time frame:
Week 12
Reported as:
Number · percentage of participants
US Specific: Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs), in Participants With EIMs at Baseline Baseline
percentage of participantsPlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)
US Specific: Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs), in Participants With EIMs at Baseline Baseline23.7 (15.2 to 32.2)29.5 (20.5 to 38.5)37.1 (27.5 to 46.7)
Statistical analysis
  • Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = 0.377 · Adjusted risk difference: 5.6 · 95% CI -6.8 to 17.9
  • Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = 0.039 · Adjusted risk difference: 13.4 · 95% CI 0.7 to 26.1
SecondaryUS Specific: Percentage of Participants With CD-Related Hospitalization

Participants with at least one admission to the hospital due to Crohn's Disease.

Time frame:
Up to Week 12
Reported as:
Number · percentage of participants
US Specific: Percentage of Participants With CD-Related Hospitalization
percentage of participantsPlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)
US Specific: Percentage of Participants With CD-Related Hospitalization11.2 (6.7 to 15.8)3.1 (0.7 to 5.6)2.1 (0.1 to 4.1)
Statistical analysis
  • Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1) · Chi-squared · p = 0.002 · Risk difference (rd): -8.1 · 95% CI -13.2 to -2.9
  • Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1) · Chi-squared · p = <0.001 · Risk difference (rd): -9.1 · 95% CI -14.1 to -4.2
SecondaryUS Specific: Percentage of Participants Without Draining Fistulas in Participants With Draining Fistulas at Baseline

Participants without draining fistulas at Week 12 in participants who had draining fistulas at baseline.

Time frame:
Week 12
Reported as:
Number · percentage of participants
US Specific: Percentage of Participants Without Draining Fistulas in Participants With Draining Fistulas at Baseline
percentage of participantsPlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)
US Specific: Percentage of Participants Without Draining Fistulas in Participants With Draining Fistulas at Baseline13.3 (0.0 to 30.5)7.1 (0.0 to 20.6)43.8 (19.4 to 68.1)
Statistical analysis
  • Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1) · Chi-squared · p = 1 · Risk difference (rd): -6.2 · 95% CI -28.1 to 15.7
  • Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1) · Chi-squared · p = 0.113 · Risk difference (rd): 30.4 · 95% CI 0.6 to 60.2
SecondaryGlobal Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission

The CDAI consists of 8 components; 6 are based on participant diary entries, participant interviews, and physical examinations, and 2 are based on laboratory analysis, and measurement of body weight and height. CDAI clinical remission of Crohn's disease is defined as CDAI \< 150.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Global Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission
percentage of participantsPlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)
Global Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission19.8 (14.1 to 25.5)42 (34.9 to 49.0)40.3 (33.4 to 47.3)
Statistical analysis
  • Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 22.1 · 95% CI 13.1 to 31.0
  • Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 20.5 · 95% CI 11.6 to 29.5
SecondaryGlobal Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response

Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Global Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response
percentage of participantsPlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)
Global Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response20.9 (15.0 to 26.7)36.6 (29.8 to 43.5)32.5 (25.8 to 39.1)
Statistical analysis
  • Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = 0.001 · Adjusted risk difference: 15.7 · 95% CI 6.8 to 24.6
  • Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = 0.008 · Adjusted risk difference: 11.8 · 95% CI 3 to 20.5
SecondaryGlobal Outside of US: Percentage of Participants With Clinical Remission

Clinical remission is defined as using the average daily Stool Frequency (SF) ≤ 2.8 and not worse than Baseline AND average daily Abdominal Pain (AP) score ≤ 1 and not worse than Baseline.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Global Outside of US: Percentage of Participants With Clinical Remission
percentage of participantsPlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)
Global Outside of US: Percentage of Participants With Clinical Remission8 (4.1 to 11.9)17.3 (11.9 to 22.6)18.3 (12.8 to 23.8)
Statistical analysis
  • Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = 0.006 · Adjusted risk difference: 9.2 · 95% CI 2.6 to 15.7
  • Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = 0.002 · Adjusted risk difference: 10.3 · 95% CI 3.7 to 16.8
SecondaryGlobal Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response

Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. CDAI clinical response is defined as reduction of CDAI ≥ 100 points from baseline.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Global Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response
percentage of participantsPlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)
Global Outside of US: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response30.0 (23.4 to 36.6)59.5 (52.5 to 66.5)60.7 (53.8 to 67.7)
Statistical analysis
  • Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 29.4 · 95% CI 19.9 to 39.0
  • Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 30.6 · 95% CI 21.1 to 40.1
SecondaryGlobal Outside of US: Change From Baseline of Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue

The FACIT-Fatigue scale is a 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four point Likert scale. The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from baseline indicates improvement.

Time frame:
Week 12
Reported as:
Least squares mean · units on a scale
Global Outside of US: Change From Baseline of Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue
units on a scalePlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)
Global Outside of US: Change From Baseline of Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue7.7 ± 0.8710.5 ± 0.8110.8 ± 0.81
Statistical analysis
  • Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1) · Mixed-Effect Model Repeat Measurement · p = 0.020 · Ls mean difference: 2.8 · 95% CI 0.4 to 5.1
  • Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1) · Mixed-Effect Model Repeat Measurement · p = 0.010 · Ls mean difference: 3.0 · 95% CI 0.7 to 5.3
SecondaryGlobal Outside of US: Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score

The IBDQ is a 32-item (ranges 1 - 7) self-report questionnaire for patients with IBD to evaluate the patient reported outcomes across 4 dimensions: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). The IBDQ total Score ranges from 32 to 224 with a higher score indicating better outcome.

Time frame:
Week 12
Reported as:
Mean · units on a scale
Global Outside of US: Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score
units on a scalePlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)
Global Outside of US: Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score27.2 (21.8 to 32.6)39.6 (34.5 to 44.7)42.2 (37.1 to 47.3)
Statistical analysis
  • Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1) · Mixed-Effect Model Repeat Measurement · p = 0.001 · Ls mean difference: 12.4 · 95% CI 5.0 to 19.8
  • Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1) · Mixed-Effect Model Repeat Measurement · p = <0.001 · Ls mean difference: 15 · 95% CI 7.7 to 22.4
SecondaryGlobal Outside of US: Percentage of Participants With Enhanced Clinical Response and Endoscopic Response

Enhanced clinical response was defined as ≥ 60% decrease in average daily Stool Frequency and/or ≥ 35% decrease in average daily Abdominal Pain score and both not worse than baseline, and/or clinical remission. Endoscopic Response was defined as a decrease in Simplified Endoscopic Score for Crohn's Disease (SES-CD) \> 50% from Baseline (or for subjects with isolated ileal disease and a Baseline SES-CD of 4, at least a 2 point reduction from Baseline).

Time frame:
Week 12
Reported as:
Number · percentage of participants
Global Outside of US: Percentage of Participants With Enhanced Clinical Response and Endoscopic Response
percentage of participantsPlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)
Global Outside of US: Percentage of Participants With Enhanced Clinical Response and Endoscopic Response7 (3.3 to 10.6)21 (15.2 to 26.8)24.1 (18.0 to 30.1)
Statistical analysis
  • Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 13.9 · 95% CI 7.1 to 20.7
  • Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 17.3 · 95% CI 10.3 to 24.2
SecondaryGlobal Outside of US:: Percentage of Participants With Endoscopic Remission

Endoscopic remission: SES-CD ≤ 4 and at least a 2 point reduction versus baseline and no subscore greater than 1 in any individual variable

Time frame:
Week 12
Reported as:
Number · percentage of participants
Global Outside of US:: Percentage of Participants With Endoscopic Remission
percentage of participantsPlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)
Global Outside of US:: Percentage of Participants With Endoscopic Remission4.3 (1.4 to 7.2)19.4 (13.8 to 25.1)20.4 (14.7 to 26.1)
Statistical analysis
  • Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 15.0 · 95% CI 8.9 to 21.2
  • Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 16.2 · 95% CI 9.9 to 22.4
SecondaryGlobal Outside of US: Percentage of Participants With Enhanced Clinical Response

Enhanced clinical response: ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in average daily AP score and both not worse than Baseline, and/or clinical remission

Time frame:
Week 4
Reported as:
Number · percentage of participants
Global Outside of US: Percentage of Participants With Enhanced Clinical Response
percentage of participantsPlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)
Global Outside of US: Percentage of Participants With Enhanced Clinical Response31.6 (24.9 to 38.2)45 (38.0 to 52.1)38.7 (31.8 to 45.7)
Statistical analysis
  • Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = 0.006 · Adjusted risk difference: 13.6 · 95% CI 4 to 23.3
  • Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = 0.142 · Adjusted risk difference: 7.1 · 95% CI -2.4 to 16.6
SecondaryGlobal Outside of US: Percentage of Participants With Ulcer-Free Endoscopy

Ulcer-free endoscopy: SES-CD ulcerated surface subscore of 0 in subjects with SES-CD ulcerated surface subscore ≥ 1 at Baseline

Time frame:
Week 12
Reported as:
Number · percentage of participants
Global Outside of US: Percentage of Participants With Ulcer-Free Endoscopy
percentage of participantsPlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)
Global Outside of US: Percentage of Participants With Ulcer-Free Endoscopy4.3 (1.4 to 7.2)13.8 (8.9 to 18.7)15.4 (10.2 to 20.5)
Statistical analysis
  • Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = 0.001 · Adjusted risk difference: 9.4 · 95% CI 3.8 to 15.1
  • Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 11.2 · 95% CI 5.3 to 17.0
SecondaryGlobal Outside of US: Percentage of Participants With Enhanced Clinical Response

Enhanced clinical response: ≥ 60% decrease in average daily SF and/or ≥ 35% decrease in average daily AP score and both not worse than Baseline, and/or clinical remission

Time frame:
Week 12
Reported as:
Number · percentage of participants
Global Outside of US: Percentage of Participants With Enhanced Clinical Response
percentage of participantsPlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)
Global Outside of US: Percentage of Participants With Enhanced Clinical Response39.1 (32.1 to 46.1)61.8 (54.9 to 68.7)59.2 (52.2 to 66.1)
Statistical analysis
  • Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 22.8 · 95% CI 13.0 to 32.5
  • Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 20 · 95% CI 10.2 to 29.9
SecondaryGlobal Outside of US: Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs), in Participants With EIMs at Baseline Baseline

Manifestations of Crohn's disease in areas of the body other than the digestive tract, including eyes, skin, joints, mouth, and liver.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Global Outside of US: Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs), in Participants With EIMs at Baseline Baseline
percentage of participantsPlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)
Global Outside of US: Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs), in Participants With EIMs at Baseline Baseline23.7 (15.2 to 32.2)29.5 (20.5 to 38.5)37.1 (27.5 to 46.7)
Statistical analysis
  • Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = 0.377 · Adjusted risk difference: 5.6 · 95% CI -6.8 to 17.9
  • Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = 0.039 · Adjusted risk difference: 13.4 · 95% CI 0.7 to 26.1
SecondaryGlobal Outside of US: Percentage of Participants With CD-Related Hospitalization

Participants with at least one admission to the hospital due to Crohn's Disease.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Global Outside of US: Percentage of Participants With CD-Related Hospitalization
percentage of participantsPlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)
Global Outside of US: Percentage of Participants With CD-Related Hospitalization11.2 (6.7 to 15.8)3.1 (0.7 to 5.6)2.1 (0.1 to 4.1)
Statistical analysis
  • Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1) · Mixed-Effect Model Repeat Measurement · p = 0.002 · Ls mean difference: -8.1 · 95% CI -13.2 to -2.9
  • Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1) · Mixed-Effect Model Repeat Measurement · p = <0.001 · Ls mean difference: -9.1 · 95% CI -14.1 to -4.2
SecondaryGlobal Outside of US: Percentage of Participants Without Draining Fistulas in Participants With Draining Fistulas at Baseline

Participants without draining fistulas at Week 12 in participants who had draining fistulas at baseline.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Global Outside of US: Percentage of Participants Without Draining Fistulas in Participants With Draining Fistulas at Baseline
percentage of participantsPlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)
Global Outside of US: Percentage of Participants Without Draining Fistulas in Participants With Draining Fistulas at Baseline13.3 (0.0 to 30.5)7.1 (0.0 to 20.6)43.8 (19.4 to 68.1)
Statistical analysis
  • Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1) · Mixed-Effect Model Repeat Measurement · p = 1.00 · Ls mean difference: -6.2 · 95% CI -28.1 to 15.7
  • Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1) · Mixed-Effect Model Repeat Measurement · p = 0.113 · Ls mean difference: 30.4 · 95% CI 0.6 to 60.2
SecondaryGlobal Outside of US: Change From Baseline in Work Productivity and Impairment Questionnaire - Crohn's Disease (WPAI-CD) Overall Work Impairment

WPAI: CD is a questionnaire used to evaluate lost productivity due to CD ; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. Total work productivity impairment takes into account both hours missed due to CD symptoms and the patient's assessment of the degree to which CD affected their productivity while working (overall work impairment \[OWI\]). WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.

Time frame:
Week 12
Reported as:
Least squares mean · units on a scale
Global Outside of US: Change From Baseline in Work Productivity and Impairment Questionnaire - Crohn's Disease (WPAI-CD) Overall Work Impairment
units on a scalePlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)
Global Outside of US: Change From Baseline in Work Productivity and Impairment Questionnaire - Crohn's Disease (WPAI-CD) Overall Work Impairment-12.253 ± 3.3683-19.576 ± 3.2747-21.013 ± 3.0074
Statistical analysis
  • Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1) · Mixed-Effect Model Repeat Measurement · p = 0.113 · Ls mean difference: -7.323 · 95% CI -16.399 to 1.753
  • Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1) · Mixed-Effect Model Repeat Measurement · p = 0.050 · Ls mean difference: -8.759 · 95% CI -17.518 to -0.001
SecondaryGlobal Outside of US: Change From Baseline in Short Form-36 (SF-36) Physical Component Summary (PCS) Score

The Short Form-36 Health Survey determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement.

Time frame:
Week 12
Reported as:
Least squares mean · units on a scale
Global Outside of US: Change From Baseline in Short Form-36 (SF-36) Physical Component Summary (PCS) Score
units on a scalePlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)
Global Outside of US: Change From Baseline in Short Form-36 (SF-36) Physical Component Summary (PCS) Score5.237 ± 0.61667.458 ± 0.57677.951 ± 0.5749
Statistical analysis
  • Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1) · Mixed-Effect Model Repeat Measurement · p = 0.008 · Ls mean difference: 2.221 · 95% CI 0.577 to 3.865
  • Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1) · Mixed-Effect Model Repeat Measurement · p = 0.001 · Ls mean difference: 2.714 · 95% CI 1.077 to 4.351
PrimaryGlobal Outside of US: Percentage of Participants With Endoscopic Response

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD \> 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).

Time frame:
Week 12
Reported as:
Number · percentage of participants
Global Outside of US: Percentage of Participants With Endoscopic Response
percentage of participantsPlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)
Global Outside of US: Percentage of Participants With Endoscopic Response19.3 (13.6 to 24.9)34.6 (27.8 to 41.3)39.8 (32.8 to 46.7)
Statistical analysis
  • Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = 0.001 · Adjusted risk difference: 15.2 · 95% CI 6.4 to 24
  • Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1) · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 20.4 · 95% CI 11.5 to 29.3

Adverse events

Collected over From first dose of study drug until 140 days following last dose of study drug, or the first dose of next period/study (up to 24 weeks), whichever occurs earlier. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (Induction Period 1)0/207 (0%)26/207 (12.6%)51/207 (24.6%)
Risankizumab 600mg (Induction Period 1)0/206 (0%)10/206 (4.9%)32/206 (15.5%)
Risankizumab 1200mg (Induction Period 1)2/205 (1%)9/205 (4.4%)32/205 (15.6%)
Period 1 Risankizumab Total2/411 (0.5%)19/411 (4.6%)64/411 (15.6%)
Risankizumab Dose 180mg (Induction Period 2)0/41 (0%)2/41 (4.9%)5/41 (12.2%)
Risankizumab 360mg (Induction Period 2)0/42 (0%)2/42 (4.8%)3/42 (7.1%)
Risankizumab 1200mg (Induction Period 2)1/42 (2.4%)3/42 (7.1%)8/42 (19%)
Placebo/Risankizumab 1200mg (Induction Period 2)0/86 (0%)9/86 (10.5%)12/86 (14%)
Period 2 Risankizumab Total1/211 (0.5%)16/211 (7.6%)28/211 (13.3%)
Most frequent serious events
Showing 10 of 48
Most frequent serious events
EventPlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)Period 1 Risankizumab TotalRisankizumab Dose 180mg (Induction Period 2)Risankizumab 360mg (Induction Period 2)Risankizumab 1200mg (Induction Period 2)Placebo/Risankizumab 1200mg (Induction Period 2)Period 2 Risankizumab Total
CROHN'S DISEASEGastrointestinal disorders20/2071/2061/2052/4110/410/422/422/864/211
ABDOMINAL PAINGastrointestinal disorders1/2070/2060/2050/4112/410/420/420/862/211
NAUSEAGastrointestinal disorders1/2070/2060/2050/4111/410/420/420/861/211
PYREXIAGeneral disorders1/2070/2061/2051/4111/410/420/420/861/211
INTESTINAL OBSTRUCTIONGastrointestinal disorders0/2070/2060/2050/4110/411/420/420/861/211
SEPSISInfections and infestations1/2070/2061/2051/4110/410/421/420/861/211
ANASTOMOTIC LEAKInjury, poisoning and procedural complications0/2070/2060/2050/4110/410/421/420/861/211
ABORTION SPONTANEOUSPregnancy, puerperium and perinatal conditions0/2070/2060/2050/4110/411/420/420/861/211
ANAEMIABlood and lymphatic system disorders0/2072/2062/2054/4110/410/420/421/861/211
ANAL STENOSISGastrointestinal disorders0/2070/2060/2050/4110/410/420/421/861/211
Most frequent other events
Most frequent other events
EventPlacebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)Period 1 Risankizumab TotalRisankizumab Dose 180mg (Induction Period 2)Risankizumab 360mg (Induction Period 2)Risankizumab 1200mg (Induction Period 2)Placebo/Risankizumab 1200mg (Induction Period 2)Period 2 Risankizumab Total
NAUSEAGastrointestinal disorders10/2075/2063/2058/4110/411/423/420/864/211
HEADACHENervous system disorders11/20711/20610/20521/4111/411/423/424/869/211
CROHN'S DISEASEGastrointestinal disorders13/2077/2063/20510/4111/410/422/421/864/211
ARTHRALGIAMusculoskeletal and connective tissue disorders8/2078/2069/20517/4112/411/421/425/869/211
ANAEMIABlood and lymphatic system disorders11/2073/2064/2057/4110/410/420/422/862/211
NASOPHARYNGITISInfections and infestations11/2078/2068/20516/4111/410/422/422/865/211

Baseline characteristics

The safety population (SA) consists of all subjects who received at least 1 dose of study medication.

Age, Categorical
Age, Categorical(Participants)Placebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)Total
<=18 years3115
Between 18 and 65 years193191198582
>=65 years1114631
Age, Continuous
Age, Continuous(years)Placebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)Total
Mean39.4 ± 13.2840.4 ± 13.5439.6 ± 12.8539.8 ± 13.22
Sex: Female, Male
Sex: Female, Male(Participants)Placebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)Total
Female10410699309
Male103100106309
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo (Induction Period 1)Risankizumab 600mg (Induction Period 1)Risankizumab 1200mg (Induction Period 1)Total
American Indian or Alaska Native0000
Asian1691439
Native Hawaiian or Other Pacific Islander2002
Black or African American128828
White176189182547
More than one race1012
Unknown or Not Reported0000
08

Study locations

403 sites
  • Phoenix VA Health Care System /ID# 162261
    Phoenix, Arizona 85012, United States
  • HonorHealth Research Institute - Shea /ID# 165825
    Scottsdale, Arizona 85258, United States
  • Digestive Disease Consultants, A Division of Arizona Digestive Health, P.C /ID# 211882
    Tempe, Arizona 85284-2604, United States
  • University of Arizona /ID# 158305
    Tucson, Arizona 85724, United States
  • Duplicate_Atria Clinical Research /ID# 164504
    Little Rock, Arkansas 72209-7040, United States
  • Southern California Res. Ctr. /ID# 211989
    Coronado, California 92118-1408, United States
  • Newport Huntington Medica /ID# 213034
    Huntington Beach, California 92648-5994, United States
  • UC San Diego Health Systems /ID# 155576
    La Jolla, California 92093, United States
  • United Medical Doctors /ID# 207887
    Los Alamitos, California 90720-3309, United States
  • TLC Clinical Research Inc /ID# 212501
    Los Angeles, California 90048, United States
  • Gastrointestinal Biosciences Clinical Trials, LLC /ID# 162655
    Los Angeles, California 90067-2001, United States
  • United Medical Doctors - Murrieta /ID# 158278
    Murrieta, California 92563, United States
  • Peak Gastroenterology Associates, PC /ID# 165832
    Colorado Springs, Colorado 80907, United States
  • Rocky Mountain Pediatric Gastroenterology /ID# 207171
    Lone Tree, Colorado 80124-6798, United States
  • Western Connecticut Medical Group /ID# 165874
    Danbury, Connecticut 06810-6000, United States
  • Seffner Premier Health Care, PA /ID# 162259
    Brandon, Florida 33510, United States
  • Clinical Research of West Florida, Inc /ID# 205864
    Clearwater, Florida 33765, United States
  • Clinical Research of West Florida, Inc /ID# 208127
    Clearwater, Florida 33765, United States
  • South Lake Pain Institute, Inc /ID# 162798
    Clermont, Florida 34711, United States
  • Omega Research Maitland, LLC /ID# 171080
    DeBary, Florida 32713-2260, United States
  • Universal Axon Clinical Research /ID# 165426
    Doral, Florida 33166, United States
  • SIH Research Mumtaz, Inc /ID# 163081
    Kissimmee, Florida 34741-4161, United States
  • Alliance Medical Research /ID# 163834
    Lighthouse Point, Florida 33064, United States
  • Cfagi Llc /Id# 202482
    Maitland, Florida 32751-6108, United States
  • University of Miami /ID# 155011
    Miami, Florida 33136, United States
  • Vista Health Research, LLC /ID# 212828
    Miami, Florida 33176-1032, United States
  • ITB Research /ID# 161278
    Miami, Florida 33176, United States
  • Coral Research Clinic /ID# 158330
    Miami, Florida 33186-4643, United States
  • South Florida Research Ph I-IV, Inc. /ID# 161825
    Miami, Florida 33193, United States
  • Gastroenterology Group Naples /ID# 165192
    Naples, Florida 34102, United States
  • Advanced Research Institute, Inc /ID# 161973
    New Port Richey, Florida 34653, United States
  • Endoscopic Research, Inc. /ID# 205903
    Orlando, Florida 32803, United States
  • IMIC Inc. Medical Research /ID# 154944
    Palmetto Bay, Florida 33157, United States
  • Clinical Research Trials of Florida, Inc. /ID# 201606
    Tampa, Florida 33607, United States
  • Atlanta Gastro Assoc /ID# 154755
    Atlanta, Georgia 30342, United States
  • Gastroenterology Associates of Central Georgia, LLC /ID# 154865
    Macon, Georgia 31201, United States
  • Northwestern University Division of GI/Hepatology /ID# 158250
    Chicago, Illinois 60611-2927, United States
  • The University of Chicago Medical Center /ID# 157113
    Chicago, Illinois 60637-1443, United States
  • NorthShore University HealthSystem /ID# 158254
    Evanston, Illinois 60201, United States
  • Southwest Gastroenterology /ID# 164764
    Oak Lawn, Illinois 60453, United States
  • Cotton-O'Neil Clinical Res Ctr /ID# 154753
    Topeka, Kansas 66606, United States
  • University of Kentucky Chandler Medical Center /ID# 157109
    Lexington, Kentucky 40536, United States
  • University of Louisville /ID# 210523
    Louisville, Kentucky 40202, United States
  • Gastroenterology Associates LLC - Jefferson Hwy /ID# 161970
    Baton Rouge, Louisiana 70809, United States
  • Houma Digestive Health Special /ID# 158253
    Houma, Louisiana 70360, United States
  • Delricht Research /ID# 206567
    New Orleans, Louisiana 70115, United States
  • Nola Research Works, LLC /ID# 161271
    New Orleans, Louisiana 70115, United States
  • Louisana Research Center, LLC /ID# 162239
    Shreveport, Louisiana 71105-6800, United States
  • MGG Group Co, Inc.Chevy Chase Clinical Research /ID# 154846
    Chevy Chase, Maryland 20815, United States
  • Gastro Center of Maryland /ID# 164766
    Columbia, Maryland 21045, United States
  • Center for Digestive Health /ID# 154697
    Troy, Michigan 48098-6363, United States
  • Gastroenterology Associates of Western Michigan, PLC d.b.a. West Michigan Clinic /ID# 161267
    Wyoming, Michigan 49519, United States
  • Mayo Clinic - Rochester /ID# 163084
    Rochester, Minnesota 55905-0001, United States
  • University of Nebraska Medical Center /ID# 210056
    Omaha, Nebraska 68198-2000, United States
  • Las Vegas Medical Research /ID# 160167
    Las Vegas, Nevada 89113, United States
  • Revival Research Institute, Inc /ID# 210986
    Las Vegas, Nevada 89128-3157, United States
  • NY Scientific /ID# 158272
    Brooklyn, New York 11235, United States
  • Saratoga Schenectady Gastroenterology Associates - Burnt Hills /ID# 213446
    Burnt Hills, New York 12027, United States
  • Intercity Advanced Gastroentertology Center /ID# 215204
    Fresh Meadows, New York 11366, United States
  • Duplicate_Long Island Clinical Research /ID# 154843
    Great Neck, New York 11021-5343, United States
  • Digestive Disease Care /ID# 211776
    New Hyde Park, New York 11040, United States
  • North Shore University Hospital /ID# 168734
    New Hyde Park, New York 11040, United States
  • NYU Langone Medical Center /ID# 160166
    New York, New York 10016-6402, United States
  • Weill Cornell Medicine /ID# 165856
    New York, New York 10022, United States
  • Icahn School of Medicine at Mount Sinai - The Mount Sinai Medical Center /ID# 165610
    New York, New York 10029, United States
  • Columbia Univ Medical Center /ID# 167545
    New York, New York 10032-3725, United States
  • Lenox Hill Hospital /ID# 168466
    New York, New York 10075, United States
  • DiGiovanna Institute for Medical Education & Research /ID# 171130
    North Massapequa, New York 11758, United States
  • Atrium Health Carolinas Medical Center /ID# 158364
    Charlotte, North Carolina 28203, United States
  • Vidant Multispecialty Clinic - Kinston /ID# 161109
    Kinston, North Carolina 28501-1589, United States
  • Wake Radiology UNC REX Healthcare - Raleigh Office /ID# 154891
    Raleigh, North Carolina 27612, United States
  • Plains Clinical Research Center, LLC /ID# 169712
    Fargo, North Dakota 58104-5925, United States
  • Tri-State Endoscopy /ID# 154939
    Cincinnati, Ohio 45219, United States
  • Cleveland Clinic Main Campus /ID# 209225
    Cleveland, Ohio 44195, United States
  • The Ohio State University /ID# 164706
    Columbus, Ohio 43210, United States
  • Optimed Research, Ltd. /ID# 167877
    Columbus, Ohio 43235, United States
  • Hometown Urgent Care and Resea /ID# 170447
    Dayton, Ohio 45424, United States
  • Great Lakes Medical Research, LLC /ID# 201774
    Mentor, Ohio 44060-6211, United States
  • Hightower Clinical /ID# 211992
    Oklahoma City, Oklahoma 73102, United States
  • Digestive Disease Specialists /ID# 170772
    Oklahoma City, Oklahoma 73112, United States
  • Adult Gastroenterology Associates - Gen 1 Research /ID# 208857
    Tulsa, Oklahoma 74136-7823, United States
  • Northwest Gastroenterology Clinic /ID# 158255
    Portland, Oregon 97210, United States
  • PennState Milton S.Hershey Med /ID# 154894
    Hershey, Pennsylvania 17033, United States
  • Children's Hospital of Pittsburgh of UPMC /ID# 212543
    Pittsburgh, Pennsylvania 15224-1334, United States
  • Digestive Disease Associates, LTD /ID# 208296
    Wyomissing, Pennsylvania 19610-2002, United States
  • Medical University of South Carolina /ID# 212859
    Charleston, South Carolina 29425, United States
  • Gastroenterology Associates, P.A. of Greenville /ID# 154919
    Greenville, South Carolina 29615-3593, United States
  • Rapid City Medical Center - GI Research /ID# 163835
    Rapid City, South Dakota 57701, United States
  • Gastro One /ID# 154757
    Germantown, Tennessee 38138, United States
  • East Tennessee Research Institute /ID# 168735
    Johnson City, Tennessee 37604, United States
  • Duplicate_Clinical Neuroscience Solutions, Inc /ID# 164179
    Memphis, Tennessee 38119, United States
  • Vanderbilt University Medical Center /ID# 157110
    Nashville, Tennessee 37232-0011, United States
  • TX Clinical Research Institute /ID# 159396
    Arlington, Texas 76012, United States
  • Inquest Clinical Research /ID# 165696
    Baytown, Texas 77521-2415, United States
  • Texas Digestive Disease Consultants /ID# 209781
    Cedar Park, Texas 78613-5028, United States
  • Texas Digestive Disease Consultants /ID# 209945
    Cedar Park, Texas 78613-5028, United States
  • DHAT Research Institute /ID# 158199
    Garland, Texas 75044-2208, United States
  • Vilo Research Group Inc /ID# 207654
    Houston, Texas 77017-2337, United States
  • CliniCore International, LLC /ID# 158191
    Houston, Texas 77027-6812, United States
  • Baylor College of Medicine - Baylor Medical Center /ID# 158194
    Houston, Texas 77030-3411, United States

Showing the first 100 of 403 sites across 43 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • D'Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV Jr, Panes J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, Ferrante M. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022 May 28;399(10340):2015-2030. doi: 10.1016/S0140-6736(22)00467-6. PubMed 35644154 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing, please refer to the link below.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Nov 2020, 35 months.

Results were first posted in Jun 2022, 1 year 6 months after primary completion. A results delay was requested in Jul 2021.

Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's 35 months is below that.

Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2017
First posted
Apr 7, 2017
StartActual
Dec 18, 2017
Primary completionActual
Nov 30, 2020
CompletionActual
May 19, 2021
Results delay requested
Jul 16, 2021
Results first posted
Jun 14, 2022
Last update
Jun 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03104413
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Apr 7, 2017
Start date
Dec 18, 2017
Primary completion
Nov 30, 2020
Completion
May 19, 2021
Results posted
Jun 14, 2022
Last update
Jun 14, 2022

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risankizumab

Start the discussion